KaNDy Therapeutics announces the appointment of Andrew Kay

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
23
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board

KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board

Stevenage, UK, 7 January 2018 - KaNDy Therapeutics, a clinical-stage company developing a potential breakthrough non-hormonal treatment for multiple debilitating symptoms of the menopause, today announces the appointment of Andrew Kay as Chairman of the Board at KaNDy Therapeutics.

Andrew Kay has extensive international board and business experience, both in biotech and at major pharmaceutical companies. Andrew is also Chairman of the Board at NeRRe Therapeutics and Chairman at Blueberry Therapeutics.  Alongside his Chairman roles, he is also the Senior Advisor to a leading VC company and a Consultant and Advisor to Boards and Executive teams in biotech and healthcare companies. He is also Director of Amulet Consulting specialising in advisory roles with biotech.

Andrew started his industry career in the pharmaceutical sector working in international roles at Novartis, AstraZeneca and Eli Lilly.  He was previously the CEO of Algeta, which was sold to Bayer for $2.9 billion in 2014 and was Chairman at Wilson Therapeutics which was bought in April 2018 by Alexion Pharmaceuticals for $855 million. Andrew has worked on a wide range of major licensing deals and has significant product launch experience including eight blockbuster launches.

Andrew gained a BPharm Hons from Nottingham University School of Pharmacy.

Mary Kerr CEO of KaNDy Therapeutics and NeRRe Therapeutics, said: " I am delighted to announce Andrews’s appointment as indepentent Chairman.  Andrew has been a trusted advisor to the Board at KaNDy for some time and I have also had the pleasure of working with him on the Board at NeRRe Therapeutics. Andrew has unrivalled experience of working internationally at biotech and pharma companies, including leading multiple successful exits and product launches, which will be invaluable to KaNDy as we progress our product candidate NT-814, which recently entered a Phase 2b trial, towards commercialisation.”

Andrew Kay, Independent Chairman of the Board of Directors of KaNDy Therapeutics, commented: “The symptoms of the menopause can be incredibly debilitating for millions of women worldwide and there is a real need for a new treatment. The data KaNDy has generated thus far has demonstrated that NT-814 could be a possible breakthrough treatment with real blockbuster potential and I am excited to work with the team at KaNDy on its continued development.”

For more information, please contact:

KaNDy Therapeutics Mary Kerr, Chief Executive Officer Tel: +44 1438 906960 Email: info@kandytherapeutics.com

Consilium Strategic Communications Mary-Jane Elliott/ Lindsey Neville/ Carina Jurs Tel: +44 (0) 20 3709 5700 KaNDyTherapeutics@consilium-comms.com

KaNDy Therapeutics is a clinical-stage company developing a potential breakthrough non-hormonal treatment for multiple debilitating symptoms of the menopause including hot flashes and sleep disturbance due to night sweats. KaNDy’s drug in development, NT-814 is a unique dual mechanism NK(neurokinin)-1,3 receptor antagonist with the potential to ‘switch off’ multiple debilitating symptoms of the menopause without the need for oestrogen exposure.

Data from a Phase 1b/2a study in post-menopausal women with troublesome hot flashes showed NT-814 was able to rapidly and profoundly reduce both the frequency and severity of hot flashes as well as sleep disturbances due to night sweats. NT-814, is now being evaluated in a Phase 2b clinical trial in postmenopausal women with moderate to severe vasomotor symptoms. Headline results are expected at the end of 2019 and NT-814 will be fully Phase 3 ready by H2 2020.

For more information please visit https://www.kandytherapeutics.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 72

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Tigo's Guidance Gap Draws Lawsuit and Investor Scrutiny

Updated Category News Views 84

A Revenue Promise Hit the Wall Solar investing can turn ugly in a hurry when a supposedly near-term catalyst gets shoved down the calendar. That is the central bruise behind the securities class action involving Tigo Energy, not some arcane accounting footnote that only lawyers can love. The complaint alleges Tigo overstated the revenue contribution it expected from its...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 85

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 109

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 125

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Healthcare: ShiftMed Enhances Scheduling at UNC Health

Updated Category News Views 389

Introduction to ShiftMed Flex at UNC Health UNC Health is taking a significant step forward by implementing ShiftMed Flex, a transformative solution aimed at enhancing workforce efficiency throughout its network. This innovative AI-driven platform is designed to improve shift participation by better matching healthcare providers' schedules with available shifts,...

Continue Reading
Rivian's Q4 Financial Performance Sparks Investor Optimism

Updated Category News Views 168

Rivian's Strong Financial Performance Rivian Automotive stock has demonstrated significant resilience and growth recently. Investors are keen to understand the factors that are propelling RIVN stock upward. The latest quarterly earnings report has highlighted Rivian’s remarkable performance, which is robust evidence of the company's progress in the competitive electric...

Continue Reading
Purple Biotech's Innovative Advancements with CAPTN-3 Antibody Platform

Updated Category News Views 295

Exciting Developments in Cancer Treatment from Purple Biotech Purple Biotech, a clinical-stage company at the forefront of oncology, has made impressive strides in its novel tri-specific T cell and NK cell engager platform, known as CAPTN-3. This innovative approach demonstrates sustained tumor regression in an in-vivo model of triple-negative breast cancer and showcases...

Continue Reading
Raytron's Thermal Technology Enhances Robotaxi Safety in All Weather

Updated Category News Views 222

Raytron's Innovative Thermal Cameras for Autonomous Driving As advancements in technology reshape our transportation systems, one major player in the field is Raytron, a leader in infrared thermal imaging. A pressing challenge in the rollout of Level 4 (L4) robotaxis is ensuring safe operation in various climatic conditions, especially during extreme weather. With...

Continue Reading
Investors Urged to Join Centene Corporation Class Action Now

Updated Category News Views 116

Centene Corporation Faces Class Action Lawsuit Levi & Korsinsky, LLP has officially notified investors about a class action lawsuit targeting Centene Corporation. This lawsuit may affect shareholders who experienced losses due to alleged securities fraud. Centene Corporation, identified by its ticker CNC, is at the center of this legal action, which has drawn attention...

Continue Reading